Sophie Pierrin-Lépinard

BNP Paribas Développement invests in SMEs and middle market companies located in France with revenues of EUR 10 - 100 million. The firm focuses on healthtech, digital health, deeptech, ecological transition and cybersecurity sectors. It provides financing for seed, early, growth and buyout stage capital requirements with an investment size of EUR 0.5 - 20 million. The firm also acts as a co-lead investor and makes follow on investments. It also acquires minority interests.

Develops therapeutics for the treatment of cancer

BVP is a venture capital investment firm focused on European emerging and early-stage companies based on high technology and with high-growth potential. The firm may also invest marginally in later-stage operations such as corporate spin offs, turnarounds and special situations. BVP specializes in sectors related to information technology, Internet and infomedia, mobile applications, electronics, semiconductors, optics and life sciences. The firm seeks to identify management teams with a demonstrated ability to manage rapid growth. Investment decisions are based on a due diligence process assessing technology distinctiveness, intellectual property protection, products, markets and competitive advantages. The firm invests either on their own or in syndication, and acquires majority or significant minority stakes.

Develops products for pediatric cardio-vascular applications

Functions as a College/University

Functions as a College/University

Offers clinically confirmed solutions for the isolation of rare cells in the blood and other fluids

Develops biopharmaceutical drugs

Kreaxi is an active manager which invests in French and European tech companies with sales up to EUR 100M. The firm invests in companies in the life sciences and information and communication technology sectors. Kreaxi manages various investment funds which invests from seed to later stage transactions.